Glaucoma
Pipeline by Development Stage
Drug Modality Breakdown
Ophthalmology is a $3.7B market with a mature, consolidating portfolio dominated by glaucoma treatments and emerging corneal/retinal therapies.
Key Trends
- Glaucoma therapeutics (prostaglandin analogs, adrenergic agents) represent 60%+ of spending but face patent cliffs 2028-2034
- Innovative mechanisms (NGF agonists, LFA-1 antagonists, RTKIs) gaining traction in dry eye and retinal disease segments
- Heavy trial activity (2,656 total) skewed toward Phase 4 (369) and Phase 3 (442), indicating mature clinical development landscape
Career Verdict
Ophthalmology offers stable mid-career opportunities with strong Commercial and Medical Affairs salaries, but limited innovation catalysts and significant patent cliff risk warrant careful timing of entry.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | LUMIGAN (Bimatoprost) | AbbVie | $697M | 19% | LOE_APPROACHING | Declining | |
| 2 | OXERVATE (Cenegermin-BKBJ) | Unspecified | $493M | 13% | PEAK | Stable | |
| 3 | XIIDRA (Lifitegrast) | Bausch + Lomb | $473M | 13% | PEAK | Stable | 7.6yr |
| 4 | INLYTA (Axitinib) | Pfizer | $467M | 13% | PEAK | Growing | 11.2yr |
| 5 | HUMIRA (Adalimumab) | AbbVie | $258M | 7% | LOE_APPROACHING | Declining |
Drug Class Breakdown
mature, losing exclusivity
peak growth in corneal disease
sustained peak sales
expanding in retinal indications
mature, multiple LOE approaching
mature, losing exclusivity
mature immunology approach
Career Outlook
StableOphthalmology offers predictable mid-career growth with strong Commercial ($158K) and Medical Affairs ($247K) compensation but faces structural headwinds: patent cliffs 2028-2034 eliminate $97M in revenue, glaucoma franchise maturity limits blockbuster potential, and modest trial volume (2,656) signals incremental R&D expansion. Best suited for professionals seeking stable roles in established therapeutic areas rather than disruptive innovation.
Breaking In
Enter via Clinical Operations or Commercial analyst roles at CROs (Syneos 210 jobs) or large diagnostics players (Labcorp 904) to build domain expertise before targeting pharma MSL/Medical Affairs positions.
For Experienced Professionals
Experienced professionals should prioritize Medical Affairs and Market Access roles leveraging mature market knowledge; avoid product-specific expertise in glaucoma due to patent cliff concentration, and consider adjacent areas (retinal, corneal) where innovation catalysts remain.
In-Demand Skills
Best For
Hiring Landscape
Ophthalmology hiring (3,202 jobs) is distributed across diagnostics/devices (Labcorp 904, Abbott 348) and pharma commercial functions rather than concentrated in R&D. Top pharmaceutical employers (Pfizer 60, AstraZeneca 100, Regeneron 168) show modest pharma-specific headcount relative to market size, suggesting outsourced CRO and distributor dependency. Medical Affairs ($247K avg salary) commands premium compensation, signaling high barrier to entry but strong mid-career upside.
Top Hiring Companies
By Department
Clinical Operations and Commercial roles offer entry-level stability ($150K-$158K); Medical Affairs commands premium salaries ($247K) but requires advanced credentials; limited R&D hiring (207 jobs) suggests constrained innovation investment.
On Market (4)
Approved therapies currently available
Competitive Landscape
43 companies ranked by most advanced pipeline stage
+13 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 4,487 patients across 50 trials
Comparison of Efficacy and Ocular Surface Assessment Between BRIDIN-plus and Combigan in Glaucoma or Ocular Hypertensive
Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells
Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN-T Eye Drops 0.15% and ALPHAGAN-P Eye Drops 0.15% in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Trial
XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway Study (GPS)
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
24-hr Intraocular Pressure Control With SIMBRINZA ®
Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)
Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked Study
SENSIMED Triggerfish in Closed Eyes
Assessing the Efficacy of DuoTrav as a Replacement Therapy in Glaucoma Patients in Russia
An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®
Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients
Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America
Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)
Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada
AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure
Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy
Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol
Effects of Anti-Glaucoma Medications on the Ocular Surface
Safety and Efficacy of Changing to DuoTrav From Prior Therapy
Use of an Ocular Telemetry Sensor in Tafluprost Treated Patients
Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Glaucoma
Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular Hypertension
A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients
Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions
24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol
Effect of Nitrous Oxide (N2O) on Intraocular Pressure in Healthy Volunteers
Efficacy and Safety of Adding Azarga to Prostaglandin Monotherapy
A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle Glaucoma
Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma
Safety and Efficacy of Brinzolamide Dosed TID With Dorzolamide Dosed TID in Reducing Intraocular Pressure in Patients With Open Angle Glaucoma or Ocular Hypertension
Circadian Ocular Perfusion Pressure and Ocular Blood Flow
An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects
Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow
How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?
Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.
Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects
Effects of Travatan Z and Xalatan on Ocular Surface Health
24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG
A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin
Value of an Intervention to Enhance Adherence in Glaucoma Patients
Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav
Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers
Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension
24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus Travoprost
IOP-Lowering Efficacy of Brinzolamide 1.0% Added to Travoprost 0.004%/Timolol 0.5% Fixed Combination as Adjunctive Therapy
Related Jobs in Ophthalmology
Marketing Coordinator
Country Portfolio Lead Vaccines
Regional Medical Scientific Director (Medical Science Liaison) - Ophthalmology (Mid-Atlantic)
Regional Medical Scientific Director (Medical Science Liaison) - Ophthalmology (Florida & PR)
Regional Medical Scientific Director (Medical Science Liaison) - Ophthalmology (Carolinas & Southern Virginia)
Regional Medical Scientific Director (Medical Science Liaison) - Ophthalmology (NYC & NJ)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.